[1] SLICHTER S J,DAVIS K,ENRIGHT H,et al.Factors affecting posttransfusion platelet increments,platelet refractoriness,and platelet transfusion intervals in thrombocytopenic patients[J].Blood,2005,105(10): 4106-4114.
[2] DOUGHTY H A,MURPHY M F,METCALFE P,et al.Relative importance of immune and non-immune causes of platelet refractoriness[J].Vox Sang,1994,66(3):200-205.
[3] STANWORTH S J,NAVARRETE C,ESTCOURT L,et al.Platelet refractoriness--practical approaches and ongoing dilemmas in patient management[J].Br J Haematol,2015,171(3):297-305.
[4] PRODGER C F,RAMPOTAS A,ESTCOURT L J,et al.Platelet transfusion: Alloimmunization and refractoriness[J].Semin Hematol,2020,57(2): 92-99.
[5] SCHMIDT A E,SAHAI T,REFAAI M A,et al.Severe platelet transfusion refractoriness in association with antibodies against CD36[J].Lab Med,2020,51(5): 540-544.
[6] SARIS A,PAVENSKI K.Human leukocyte antigen alloimmunization and alloimmune platelet refractoriness[J].Transfus Med Rev,2020,34(4):250-257.
[7] PAVENSKI K,FREEDMAN J,SEMPLE J W.HLA alloimmunization against platelet transfusions: pathophysiology,significance,prevention and management[J].Tissue Antigens,2012,79(4):237-245.
[8] FOREST S K,HOD E A.Management of the platelet refractory patient[J].Hematol Oncol Clin North Am,2016,30(3):665-677.
[9] PETZ L D,GARRATTY G,CALHOUN L,et al.Selecting donors of platelets for refractory patientson the basis of HLA antibody specificity[J].Transfusion,2000,40(12):1446-1456.
[10] HOD E,SCHWARTZ J.Platelet transfusion refractoriness[J].Br J Haematol,2008,142(3):348-360.
[11] 胡咏梅,武晓洛,胡志红,等.关于中国人体表面积公式的研究[J].生理学报,1999,51(1):45-48.
[12] TRIAL TO REDUCE ALLOIMMUNIZATION TO PLATELETS STUDY GROUP.Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions[J].N Engl J Med,1997,337(26):1861-1870.
[13] DALY P A,SCHIFFER C A,AISNER J,et al.Platelet transfusion therapy.One-hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations[J].JAMA,1980,243(5): 435-438.
[14] BISHOP J F,MATTHEWS J P,MCGRATH K,et al.Factors influencing 20-hour increments after platelet transfusion[J].Transfusion,1991,31(5):392-396.
[15] O'CONNELL B,LEE E J,SCHIFFER C A.The value of 10-minute posttransfusion platelet counts[J].Transfusion,1988,28(1):66-67.
[16] SCHIFFER C A,BOHLKE K,DELANEY M,et al.Platelet transfusion for patients with cancer: American society of clinical oncology clinical practice guideline update[J].J Clin Oncol,2018,36(3): 283-299.
[17] SCHMIDT A E,REFAAI M A,COPPAGE M.HLA-mediated platelet refractoriness[J].Am J Clin Pathol,2019,151(4):353-363.
[18] BISHOP J F,MATTHEWS J P,YUEN K,et al.The definition of refractoriness to platelet transfusions[J].Transfus Med,1992,2(1):35-41. |
